IMR Press / EJGO / Volume 38 / Issue 2 / DOI: 10.12892/ejgo3470.2017

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Forkhead box protein 3 (FoxP3) mRNA as a diagnostic marker in ovarian tumors: a pilot study
Show Less
1 Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Cairo, Abbasia, Egypt
2 Gynecologic Oncology Unit, Ain Shams University Maternity Hospital, Cairo, Abbasia, Egypt
Eur. J. Gynaecol. Oncol. 2017, 38(2), 251–256; https://doi.org/10.12892/ejgo3470.2017
Published: 10 April 2017
Abstract

Purpose: To assess the diagnostic performance of forkhead box protein 3 (FoxP3) mRNA in ovarian tumors. Materials and Methods: Using quantitative real time reverse transcription PCR (q-RT-PCR), FoxP3 mRNA level was measured in fresh frozen ovarian tumors and its diagnostic performance was compared to those of preoperative serum CA125 and risk of malignancy index (RMI). Results: FoxP3 mRNA was differentially expressed in the malignant (n = 25) and benign (n = 25) groups, yet without statistically significant differences; positivity rate: 15/25 vs. 10/25; p = 0.157, median: 0.429 vs. 0.046; p = 0.684, and mean ± SD: 73.75 ± 234.68 vs. 247.09 ± 792.17; p = 0.301. Although it showed much less diagnostic performance (AUC: 0.534), FoxP3 mRNA enhanced the diagnostic sensitivity and specificity of both CA125 and RMI (96% and 100%, for both). Conclusion: FoxP3 mRNA may not be good diagnostic marker in ovarian tumors; however it may prove valuable in defining underlying tumor molecular signature.
Keywords
Ovarian tumor
q-RT-PCR
FoxP3 mRNA
CA125
Treg
Share
Back to top